title: Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors.
abstract: The receptor tyrosine kinase EPHB2 has recently been shown to be a direct transcriptional target of TCF/beta-catenin. Premalignant lesions of the colon express high levels of EPHB2 but the expression of this kinase is reduced or lost in most colorectal carcinomas. In addition, inactivation of EPHB2 has been shown to accelerate tumorigenesis initiated by APC mutation in the colon and rectum. In this study, we investigated the molecular mechanisms responsible for the inactivation of EPHB2 in colorectal tumors. We show here the presence of mutations in repetitive sequences in exon 17 of EPHB2 in 6 of 29 adenomas with microsatellite instability (MSI), and 101 of 246 MSI carcinomas (21% and 41%, respectively). Moreover, we found EPHB2 promoter hypermethylation in 54 of the 101 colorectal tumors studied (53%). Importantly, EPHB2 expression was restored after treatment of EPHB2-methylated colon cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. In conclusion, in this study, we elucidate the molecular mechanisms of inactivation of EPHB2 and show for the first time the high incidence of frameshift mutations in MSI colorectal tumors and aberrant methylation of the regulatory sequences of this important tumor suppressor gene.
authors.affiliation: Molecular Oncology and Aging Group, Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Hospital Research Institute, Barcelona, Spain.
authors.forename: Hafid
authors.initials: H
authors.lastname: Alazzouzi
authors.forename: Veronica
authors.initials: V
authors.lastname: Davalos
authors.forename: Antti
authors.initials: A
authors.lastname: Kokko
authors.forename: Enric
authors.initials: E
authors.lastname: Domingo
authors.forename: Stefan M
authors.initials: SM
authors.lastname: Woerner
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Wilson
authors.forename: Lars
authors.initials: L
authors.lastname: Konrad
authors.forename: Päivi
authors.initials: P
authors.lastname: Laiho
authors.forename: Eloi
authors.initials: E
authors.lastname: Espín
authors.forename: Manel
authors.initials: M
authors.lastname: Armengol
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamamoto
authors.forename: John M
authors.initials: JM
authors.lastname: Mariadason
authors.forename: Johannes F
authors.initials: JF
authors.lastname: Gebert
authors.forename: Lauri A
authors.initials: LA
authors.lastname: Aaltonen
authors.forename: Simo
authors.initials: S
authors.lastname: Schwartz
authors.forename: Diego
authors.initials: D
authors.lastname: Arango
mesh_terms: D000236:Adenoma / Q000201:enzymology / Q000235:genetics; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics*; D018899:CpG Islands; D019175:DNA Methylation; D004789:Enzyme Activation; D005091:Exons; D016368:Frameshift Mutation; D015971:Gene Expression Regulation, Enzymologic; D020868:Gene Silencing; D006801:Humans; D018895:Microsatellite Repeats / Q000235:genetics; D011401:Promoter Regions, Genetic; D036183:Receptor, EphB2 / Q000235:genetics* / Q000378:metabolism; D012091:Repetitive Sequences, Nucleic Acid
chemical_list: D036183:Receptor, EphB2